How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.date.accessioned | 2008-11-03T18:54:52Z | |
dc.date.available | 2009-11-06T18:12:56Z | en_US |
dc.date.issued | 2008-10 | en_US |
dc.identifier.citation | Lok, Anna S. F. (2008). "How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting." Liver Transplantation 14(S2): S8-S14. <http://hdl.handle.net/2027.42/61245> | en_US |
dc.identifier.issn | 1527-6465 | en_US |
dc.identifier.issn | 1527-6473 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/61245 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18825720&dopt=citation | en_US |
dc.description.abstract | Key Points 1 Hepatitis B virus variants with antiviral drug–resistant mutations and/or hepatitis B immune globulin–resistant mutations are the main cause of hepatitis B virus reinfections post–liver transplant. 2 Early diagnosis of antiviral drug resistance and prompt initiation of rescue therapy are important in preventing hepatitis flares and hepatic decompensation. 3 Virologic breakthrough is the first indication of antiviral drug resistance. 4 Genotypic resistance testing should be performed when possible to avoid unnecessary modification of treatment in patients who do not have confirmed antiviral drug resistance and to permit appropriate selection of rescue therapy in those who have confirmed antiviral drug resistance. 5 Choice of rescue therapy requires knowledge of the past history of hepatitis B virus treatments and virologic response to those treatments, patterns of mutations detected at the time of virologic breakthrough, and in vitro cross-resistance data. 6 Occurrence of antiviral drug resistance can be reduced by the use of the most potent nucleos(t)ide analogue(s) with the highest genetic barrier to resistance, emphasis of medication compliance, and close monitoring of virologic response. Liver Transpl 14:S8–S14, 2008. © 2008 AASLD. | en_US |
dc.format.extent | 96555 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Surgery | en_US |
dc.title | How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Surgery and Anesthesiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, MI ; FAX: 734-936-7392 ; Division of Gastroenterology, University of Michigan Hospitals, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109 | en_US |
dc.identifier.pmid | 18825720 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/61245/1/21616_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/lt.21616 | en_US |
dc.identifier.source | Liver Transplantation | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.